Use of antidiabetic drugs in the U.S., 2003-2012

Diabetes Care

Volumn 37, Issue 5, 2014, Pages 1367-1374

  Hampp, Christian ^a   Borders Hemphill, Vicky ^a   Moeny, David G ^a   Wysowski, Diane K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BROMOCRIPTINE MESILATE; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; METFORMIN; PRAMLINTIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG USE; HUMAN; LONGITUDINAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY; RISK ASSESSMENT; TREND STUDY; UNITED STATES;

EID: 84899119505     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2289     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States [Internet], 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available from http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed 28 May 2013
2. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009;32:2225-2229
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
4. Gregg EW, Chen H, Wagenknecht LE, et al.; Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012;308:2489-2496
5. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248-256, e5
6. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-1576
7. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-1585
8. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613-1624
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
10. European Medicines Agency. European Medicines Agency Recommends Suspension of Avandia, Avandamet and Avaglim [Internet], 2010. London, U.K., European Medicines Agency. Available from http://www.ema.europa.eu/ema/index. jsp?curl=pages/news-and-events/news/2010/09/news-detail-001119.jsp&mid= WC0b01ac058004d5c1. Accessed 29 May 2013
11. U.S. Food and Drug Administration. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-Containing Medicines Including Avandia, Avandamet, and Avandaryl [Internet], 2011. Silver Spring, MD, U.S. Food and Drug Administration. Available from http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm. Accessed 29 May 2013
12. U.S. Food and Drug Administration. Information for Healthcare Professionals: Pioglitazone HCl (Marketed as Actos, Actoplus Met, and Duetact) [Internet], 2007. Silver Spring, MD, U.S. Food and Drug Administration. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124178.htm. Accessed 29 ay 2013
13. U.S. Food and Drug Administration. Actos (Pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer [Internet], 2011. Silver Spring, MD, U.S. Food and Drug Administration. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm226257.htm. Accessed 29 May 2013
14. U.S. Census Bureau. National Population Projections [Internet], 2012. Washington, DC, U.S. Census Bureau. Available from http://www.census.gov/ population/projections/files/downloadables/NP2012-D1.csv. Accessed 30 May 2013
15. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
16. Johnson JA, Pohar SL, Secnik K, Yurgin N, Hirji Z. Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001. BMC Health Serv Res 2006;6:159
17. Theodorou A, Johnson K, Ward M, Szychowski JA. 2010 drug utilization and cost trends for antidiabetic agents. Am J Pharm Benefits 2011;3:54-61
18. Margolis DJ, Leonard CE, Razzaghi H, et al. Utilization of Antidiabetic Drugs Among Medicare Beneficiaries With Diabetes, 2006-2009, Data Points Publication Series [Internet], 2012. Rockville, MD, Agency for Healthcare Research and Quality. Available from http://www.ncbi.nlm.nih.gov/books/NBK92702/ . Accessed 20 January 2014
19. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 2003;26:1852-1855 (Pubitemid 36929132)
20. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
21. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-928 (Pubitemid 27224940)
22. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002;162:434-437 (Pubitemid 34150645)
23. Kennedy L, Herman WH; GOAL A1C Study Team. Renal status among patients using metformin in a primary care setting. Diabetes Care 2005;28:922-924 (Pubitemid 40434496)
24. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab 2010;12:1079-1083
25. Horlen C, Malone R, Bryant B, et al. Frequency of inappropriate metformin prescriptions. JAMA 2002;287:2504-2505
26. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008;14:523-531
27. Stewart KA, Natzke BM, Williams T, Granger E, Casscells SW, Croghan TW. Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone. Pharmacoepidemiol Drug Saf 2009;18:1048-1052
28. Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care 2010;33:823-825
29. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning - geographic variation in the use of rosiglitazone. N Engl J Med 2010;363:2081-2084
30. Shi L, Zhao Y, Szymanski K, Yau L, Fonseca V. Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. J Diabetes Complications 2011;25:143-150
31. Marks DH. Drug utilization, safety and clinical use of Actos and Avandia. Int J Risk Saf Med 2013;25:39-51
32. Hurren KM, Taylor TN, Jaber LA. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. Diabetes Res Clin Pract 2011;93:49-55
33. Rawson NS, Terres JA. Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010. BMC Res Notes 2013;6:82
34. Ruiter R, Visser LE, van Herk-SukelMP, et al. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. Drug Saf 2012;35:471-480
35. Morrow RL, Carney G, Wright JM, Bassett K, Sutherland J, Dormuth CR. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Open Med 2010;4:e50-e59
36. U.S. Food and Drug Administration. FDA Requires Removal of Certain Restrictions on the Diabetes Drug Avandia [Internet]. Silver Spring, MD, U.S. Food and Drug Administration. Available from http://www.fda.gov/newsevents/ newsroom/pressannouncements/ucm376516.htm. Accessed 3 December 2013